While the introduction of novel therapies has led to substantial improvements in the outcomes of patients with newly diagnosed multiple myeloma, there remains a high-risk population of patients who ...

Darzalex Faspro reduced the risk of disease progression to active multiple myeloma or death by 51% compared with active monitoring. The Food and Drug Administration (FDA) has approved Darzalex Faspro ...

"Medical Journeys" is a set of clinical resources reviewed by physicians, meant for the medical team as well as the patients they serve. Each episode of this journey through a disease state contains ...

Entitled “International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma,” the peer-reviewed article, published online on ...

The MarketWatch News Department was not involved in the creation of this content. SHANGHAI and NANJING, China and PLEASANTON, Calif., Dec. 7, 2025 /PRNewswire/ -- IASO Biotechnology ("IASO Bio"), a ...

CAR-T treatment landscape in multiple myeloma basically has changed dramatically over the past few years.

Identifying risk factors enables physicians to implement targeted intervention strategies and preventive measures, aiming to reduce the disease burden and minimize the risk of relapse. Multiple ...

Phase 3 AQUILA study showed DARZALEX FASPRO ® significantly reduced the risk of progression to active multiple myeloma or death by 51 percent compared to active monitoring Landmark approval supports ...

Results from a new clinical trial suggest that a high-fiber plant-based diet could benefit patients at risk for developing multiple myeloma, the second most common type of blood cancer. The study ...

RARITAN, N.J., May 20, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) announced today the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) voted (6-2) in favor of ...

SAN DIEGO, Nov. 7, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that Johnson & Johnson received U.S. Food and Drug Administration (FDA) approval of a new ...